The role of granulocyte colony‑stimulating factor in breast cancer development: A review
- Li Liu
- Yangyang Liu
- Xiaohua Yan
- Chong Zhou
- Xiangyang Xiong
Affiliations: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Anesthesiology, First Clinical Medical College, School of Medicine, Nanchang University, Nanchang, Jiangxi 330006, P.R. China
- Published online on: March 10, 2020 https://doi.org/10.3892/mmr.2020.11017
Copyright: © Liu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Granulocyte‑colony‑stimulating factor (G‑CSF) is a member of the hematopoietic growth factor family that primarily affects the neutrophil lineage. G‑CSF serves as a powerful mobilizer of peripheral blood stem cells and recombinant human G‑CSF (rhG‑CSF) has been used to treat granulocytopenia and neutropenia after chemotherapy for cancer patients. However, recent studies have found that G‑CSF plays an important role in cancer progression. G‑CSF expression is increased in different types of cancer cells, such as lung cancer, gastric cancer, colorectal cancer, invasive bladder carcinoma, glioma and breast cancer. However, it is unclear whether treatment with G‑CSF has an adverse effect. The current review provides an overview of G‑CSF in malignant breast cancer development and the data presented in this review are expected to provide new ideas for cancer therapy.